Please assess the completion status of the following clinical trial:

Trial Title: Glyburide vs Glucovance in the Treatment of GDM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational diabetes~* Pregnancy \> 12 weeks gestation~* Ability to give consent~Exclusion Criteria:~* Inability to consent to the study~* Pre-existing diabetes~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Serum creatinine \>1~* Liver disease~* Allergy to sulfa;~* Allergy to glyburide;~* Allergy to metformin;~* Fetal anomalies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glyburide (Type: ACTIVE_COMPARATOR): * Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~* The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.~* The dose of glyburide will be increased as needed to a maximum of 20mg /day.~* Antenatal testing will be initiated at 28 weeks~* Patients will receive monthly growth scans
- Glucovance (Type: ACTIVE_COMPARATOR): * Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~* The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.~* Patients will receive monthly growth scans~* Antenatal testing will be initiated at 28 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).